Tesamorelin
ProtocolProtocol design for Tesamorelin starts with pharmacokinetics and ends with calendar planning. The compound's ~30 min half-life via subq administration places it in the multi-daily-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.
Key Takeaways
Scheduling lens: Tesamorelin's ~30 min half-life via subq places it in the multi-daily-dosing bucket. Mechanism: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Stimulates pituitary GH release, raising IGF-1 and producing marked reduction in visceral adipose tissue with relative sparing of subcutaneous fat. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Tesamorelin.
Stack scheduling with other compounds
When Tesamorelin is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Tesamorelin protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Tesamorelin schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
Daily and weekly timing
Tesamorelin with a ~30 min half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1x daily SubQ, with consistency mattering more than the absolute clock time of any single dose.
Schedule design for Tesamorelin in loading phase starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
The most-asked scheduling question for Tesamorelin in cycle length is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
For daily timing scheduling, Tesamorelin is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
Schedule design for Tesamorelin in wash-out starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 1-2 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1-2 mg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 1-2 mg | 1x daily SubQ |
| Maintenance phase | SubQ | 1-2 mg | Ongoing with periodic pauses |
Dose timing for Tesamorelin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
Tesamorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- Tesamorelin + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Tesamorelin's mechanism in protocol / scheduling / cycling protocols.
- Tesamorelin + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Tesamorelin's mechanism in protocol / scheduling / cycling protocols.
- Tesamorelin + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Tesamorelin's mechanism in protocol / scheduling / cycling protocols.
- Tesamorelin + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Tesamorelin's mechanism in protocol / scheduling / cycling protocols.
Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated.
Lens-specific safety considerations for protocol / scheduling / cycling use of Tesamorelin: Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Tesamorelin | Stabilised GHRH analogue | ~30 min | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Cycle length and off-cycle period?
Best practice for re-cycling?
Stack timing relative to training and meals?
Can I shift my schedule with travel?
What should I look for in Tesamorelin sourcing and quality?
How should Tesamorelin be stored and reconstituted?
Start a Tesamorelin Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified Tesamorelin and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 5135 Da
- Sequence length
- 44 aa
- Half-life
- ~30 min
- WADA
- Banned (S2)
- FDA
- Approved (Egrifta 2010 for HIV lipodystrophy)
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Tesamorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for Tesamorelin
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised